- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
This report is an account of the Region’s progress in developing and implementing NAPs. The report provides a platform to track what is going well, and to identify areas where extra efforts are needed. In the report, the regional roadmap for strengthening national AMR prevention and containment programmes is analysed with a specific methodology. The results gathered have been compiled to contribute to country profiles which make the report more useful.
Keywords: AMR, situation analysis, surveillance, prevention
The 90-90-90 targets and the HIV testing and treatment cascade are two ways of looking at the same data. The targets were instrumental in galvanizing global action for HIV treatment access.
Keywords: HIV, PLHIV, targets, treatment, testing
This report highlights the key results achieved over Phase II of the MHTF, from 2014 to 2016, structured around the three cross-cutting principles of accountability, equality of access and quality of care, as outlined in the MHTF Business Plan Phase II (2014-2017). The report foregrounds the MHTF’s role in supporting health systems strengthening, and addresses its catalytic nature, its promotion of sustainability and its strong emphasis on advancing innovation.
This book represents the consolidated knowledge and experience related to the policies and management of universal access to ART in Thailand. It aims to serve as an important tool to share knowledge with and advocate the policy of universal health coverage (UHC) to policymakers in the other developing nations that are working towards achieving UHC inclusive of the continuum of HIV and AIDS care services
Keywords: Thailand, HIV, PLHIV, ART, treatment, health system
This WHO Global hepatitis report describes, for the first time, the global and regional estimates on viral hepatitis in 2015, setting the baseline for tracking progress in implementing the new global strategy.
The report focuses on hepatitis B and C, which are responsible for 96% of all hepatitis mortality. It presents data along the five strategic directions (strategic information, interventions, equity, financing and innovation) – key pillars of the GHSS to facilitate monitoring of progress in countries, regions and globally, and to measure the impact of interventions on reducing new infections and saving lives between 2015 and 2030.
Download Executive Summary
WHO has recommended adopting drug regimens with high potency, lower toxicity, high genetic barriers to resistance, usefulness across different populations and lower cost. The use of optimized drug regimens can improve the durability of the treatment and quality of care of people living with HIV.
Adopting optimized antiretroviral (ARV) drug regimens can significantly affect the speed at which the 90 –90 –90 targets are achieved, enhancing access to treatment and improving treatment outcomes with impact on treatment adherence, viral suppression and the quality of life of people living with HIV, reducing pressures on health systems and the risk of HIV transmission.
Viral hepatitis now ranks as the seventh leading cause of mortality worldwide. Although mortality due to communicable diseases has declined globally, the absolute burden and relative ranking of viral hepatitis as a cause of mortality has increased between 1990 and 2013.
Viral hepatitis causes at least as many, if not more, deaths annually compared with TB, AIDS, or malaria. Mortality due to viral hepatitis is increasing with time, while that due to TB, HIV and malaria is declining. Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections account for more than 90% of viral hepatitis-related deaths and disability, with hepatitis A and E being responsible for the remaining.
The WHO/HIVResNet Laboratory Operational Framework describes how WHO HIVResNet laboratories function to support national, regional, and global HIV drug resistance (HIVDR) surveillance by providing accurate genotyping results in a standardized format according to WHO specifications.
Keywords: HIV, laboratory services, drug resistance
Drug use and supply have been a sensitive and high-priority issue for successive governments in China since at least the Opium Wars in the mid-19th century. China’s policy response to drug use relies on punishment and coercion as central components, including compulsory detoxification, detention in labour camps or so-called ‘rehabilitation’ facilities, and compulsory registration with law enforcement authorities resulting in surveillance and random interrogations.
Yet, in the late-1990s, in a policy move that appeared to emphasize healthcare instead of punishment for people who inject drugs, China began implementing the world’s largest scale-up provision of opioid substitution therapy (OST) and needle and syringe programmes (NSP) – two critical harm reduction measures for preventing HIV transmission. However, the overall approach towards people who use drugs remains punitive and stigmatising in China. As drug use continues to rise and expand across a greater range of drugs (especially synthetic drugs such as methamphetamine), as well as amongst younger age groups, China requires a comprehensive system of evidence-based and humane drug treatment and harm reduction services capable of advancing the health and quality of life of individuals and communities.
Keywords: China, HIV, PWID, NSPs and OST, drugs, health, law
This document provides key considerations on when clinically stable children, adolescents and women who are pregnant or breastfeeding as well as members of key populations (people who inject drugs, sex workers, men who have sex with men, transgender people and people living in prisons and closed settings) can benefit from access to ART services for clinically stable clients, including less frequent clinic visits and multi-month refills for ART and other medications. The guidance provides the rationale and the approach to expand differentiated ART delivery to populations of people living with HIV who previously may not have been considered “eligible” for ART delivery models for clinically stable clients.
Keywords: HIV, ART, treatment, health care